{'fraction_non_alphanumeric': 0.018026565464895637, 'fraction_numerical': 0.0, 'mean_word_length': 5.279761904761905, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[A new paradigm in the treatment of ischemia. Learning from drosophila].

Ischemia is one of the major concerns of clinicians who are constantly confronted with it, both in surgical and pathological aspects. The consequences of ischemic stress are dramatic and can lead to organic, motor or cognitive disabilities. Currently, there is no identified specific molecular target whose targeting could be beneficial in this area. The drosophila melanogaster fly, used as a model animal, has made it possible to highlight a major advance by allowing the identification of a completely new pharmacological target whose inhibition significantly increases tolerance to hypoxia. Applied to a preclinical model of renal transplantation, this new approach significantly improves the functional recovery of the graft in the long term. This mini-synthesis retraces the steps that made it possible to transfer to higher mammals a concept highlighted in Drosophila that clearly shows, beyond basic research, the contribution that a model organism can make to the clinic.